TABLE 3.
Univariable Analysis OR (95% CI), | p-value | Multivariable Analysis OR (95% CI) | p-value | |
---|---|---|---|---|
Minimum Breast Density | 1.38 (1.04–1.83) | 0.026 | 1.37 (1–1.86) | 0.049 |
Age | 0.99 (0.97–1) | 0.138 | ||
Race (White) | 1.01 (0.59–1.81) | 0.967 | ||
BMI | 0.96 (0.93–1) | 0.052 | ||
Mammogram/US detected | 0.97 (0.52–1.57) | 0.958 | ||
MRI Performed | 0.71 (0.37–1.34) | 0.289 | ||
Tumor size (cm) | 0.9 (0.69–1.16) | 0.424 | ||
SLN positive | 0.78 (0.4–1.42) | 0.443 | ||
Multifocal Disease | 4.34 (2.78–6.76) | <0.001 | 4.24 (2.65–6.76) | <.001 |
pT2 versus pT1 | 0.93 (0.52–1.57) | 0.781 | ||
Other | 0.28 (0.02–1.36) | |||
Associated DCIS | 1.83 (1.02–3.53) | 0.054 | ||
EIC present | 4.49 (2.44–8.14) | <0.001 | 3.5 (1.8–6.84) | <.001 |
ER positive | 0.96 (0.49–2.06) | 0.906 | ||
PR positive | 1.04 (0.62–1.83) | 0.878 | ||
HER2 positive | 2.05 (1.04–3.83) | 0.029 | 1.52 (0.74–3.1) | 0.251 |
OR odds ratio, CI confidence interval, US ultrasound, SLN sentinel lymph node, pT pathologic tumor stage, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, EIC extensive intraductal component, ER estrogen receptor, PR progesterone receptor